MSDC-0602K improves liver enzymes, glycemic control in NASH with diabetes

BOSTON — Treatment with MSDC-0602K safely produced positive effects on glycemic control along with consistent improvement in liver enzymes and noninvasive hepatic markers in patients with nonalcoholic steatohepatitis and type 2 diabetes, according to data presented at The Liver Meeting 2019.
“When we talk about NASH, we talk about a disease that’s in the setting of overnutrition. Overnutrition can result in insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease and NASH, which frequently coexist,” Stephen A. Harrison, MD, medical director of Pinnacle

Source link

Related posts

Hydrogen Breath is Not from Bikini Atoll


POEM Promising as Initial Therapy for Achalasia


Maternal use of non-TNF inhibitor biologic, tofacitinib pose minimal infectious risk to offspring


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy